New compounds could reduce alcoholics' impulse to drink

August 19, 2015, American Chemical Society
Image: John White

Alcoholism inflicts a heavy physical, emotional and financial toll on individuals and society. Now new discoveries and promising animal studies are offering a glimmer of hope that a new class of drugs could treat the disease without many of the unwanted side effects caused by current therapies.

Researchers are presenting the results of their work today at the 250th National Meeting & Exposition of the American Chemical Society (ACS).

"Alcoholism is a major problem in the U.S.," V. V. N. Phani Babu Tiruveedhula says. "Alcohol abuse costs almost $220 billion to the U.S. economy every year. That's a shocking number. We need a better treatment right now." Tiruveedhula is a graduate student at the University of Wisconsin, Milwaukee.

The exact causes of alcoholism are not well understood, but the researchers explain that the urge to drink is related to the brain's pleasure centers. Scientists have found that alcohol triggers the brain to release dopamine, the same neurochemical whose levels increase in response to pleasurable behavior like eating, sex or listening to music.

Some drugs currently available to treat alcoholism are aimed at dopamine. "They dampen out the dopamine system a little bit, so you don't get so happy when you have an alcoholic beverage," says James Cook, Ph.D., a chemist at the University of Wisconsin, Milwaukee, who advises Tiruveedhula. But these medications, derived from a class of compounds called opioid antagonists, cause depression in some patients, Cook notes. And they're addictive themselves, which can lead to drug abuse. Valium is an example of another common drug used to treat alcoholism that is also addictive.

Looking for an alternative, Cook focused on molecules known to cause some of the same results as Valium and the opioid antagonists without the unwanted side effects. For almost two decades, Cook collaborated with the late Harry June, Ph.D., a psychopharmacologist at Howard University. They conducted laboratory tests to understand the effects of these new compounds and to discover which ones work best.

Now, Tiruveedhula has made several of these promising beta-carboline compounds that could represent the future of . Tiruveedhula simplified their manufacture from eight steps to just two, while increasing the yield tenfold and eliminating unwanted byproducts. Cook says these potential medications could be taken orally.

In tests using rats bred to crave , the scientists found that administering these compounds drastically diminished the rats' drinking. What's more, they observed very few of the common to alcoholism treatment drugs, such as depression and losing the ability to experience pleasure. The drugs appeared to reduce anxiety in "alcoholic" rats, but not in control rats. Because this is different from what is seen with current drugs, the researchers think the result hints that the new compounds work much differently than opioid antagonists. As such, the beta-carbolines may also be less addictive.

"What excites me is the compounds are orally active, and they don't cause depression like some drugs do," says Cook.

The group is continuing to test the compounds in additional animal studies. Cook has patented several of the most promising , and he is starting to explore possible partnerships with drug makers that could lead to medications.

If everything works out, Cook says, a could be ready for the market in five to six years.

Explore further: Scientists identify new compounds that may treat depression rapidly with few side effects

More information: Design and regiospecific synthesis of 3-substituted β-carbolines as a GABAA subtype selective agents for the treatment of alcohol abuse, the 250th National Meeting & Exposition of the American Chemical Society (ACS).

Related Stories

Scientists identify new compounds that may treat depression rapidly with few side effects

July 13, 2015
A new study by researchers at University of Maryland School of Medicine has identified promising compounds that could successfully treat depression in less than 24 hours while minimizing side effects. Although they have not ...

A new target for alcoholism treatment: Kappa opioid receptors

May 22, 2014
The list of brain receptor targets for opiates reads like a fraternity: Mu Delta Kappa. The mu opioid receptor is the primary target for morphine and endogenous opioids like endorphin, whereas the delta opioid receptor shows ...

Researchers find anti-seizure drug may reduce alcohol consumption

April 17, 2014
Researchers from Boston University School of Medicine (BUSM) have discovered that the anti-seizure drug ezogabine, reduced alcohol consumption in an experimental model. The findings, reported in the American Journal of Drug ...

Study links brain inflammation triggered by chronic pain to anxiety and depression

June 9, 2015
Brain inflammation caused by chronic nerve pain alters activity in regions that regulate mood and motivation, suggesting for the first time that a direct biophysical link exists between long-term pain and the depression, ...

Taste of beer, without effect from alcohol, triggers dopamine release in the brain

April 15, 2013
The taste of beer, without any effect from alcohol itself, can trigger dopamine release in the brain, which is associated with drinking and other drugs of abuse, according to Indiana University School of Medicine researchers.

Recommended for you

Warning labels on alcohol containers highly deficient, new research shows

May 21, 2018
Current health warning labels on alcohol beverage containers in New Zealand are highly deficient, new research from the University of Otago, Wellington shows.

Serving smaller alcoholic drinks could reduce the U.K.'s alcohol consumption

May 14, 2018
New research published in Addiction, conducted by researchers from the Universities of Liverpool and Sheffield, highlights the potential benefits of reducing the standard serving size of alcoholic beverages.

Anti-alcoholism drug shows promise in animal models

May 3, 2018
Scientists at The University of Texas at Austin have successfully tested in animals a drug that, they say, may one day help block the withdrawal symptoms and cravings that incessantly coax people with alcoholism to drink. ...

FDA-approved drugs to treat diabetes and obesity may reduce cocaine relapse and help addicted people break the habit

April 28, 2018
Cocaine and other drugs of abuse hijack the natural reward circuits in the brain. In part, that's why it's so hard to quit using these substances. Moreover, relapse rates hover between 40 and 60 percent, similar to rates ...

Buprenorphine may be safer than methadone if treatment duration is longer, study suggests

April 20, 2018
The less commonly prescribed opioid substitute buprenorphine may be safer than methadone for problem opioid users, especially if used during the first month of treatment, according to a study which includes University of ...

Binge-eating mice reveal obesity clues

April 9, 2018
Obesity is a growing issue in many countries, accelerated by easy access to calorie-dense foods that are pleasurable to eat (known as an 'obesogenic environment'). But while it's clear that eating too much leads to weight ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.